All In Biotech

Drug Trial Radar · NCT07655362

Baxdrostat and Ventricular Remodeling

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Baxdrostat on Ventricular Remodeling

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Jun 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Subodh VermaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AstraZeneca
First posted
Jun 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this trial is to learn whether adding the blood pressure medication baxdrostat (Baxfendy) to standard-of-care medical therapies will beneficially change the heart structure and function of adults who have high blood pressure, thickened left heart walls, and are at risk for heart or kidney disease. To determine if baxdrostat improves heart structure and function, the participants will: * take a baxdrostat or a placebo (a look-alike tablet that contains no drug) tablet once a day for 12 months * undergo a safe and non-invasive cardiac magnetic resonance imaging scan (to measure heart mass, stiffness and function) at the beginning of the study and 12 months later * visit the clinic for checkups and blood or urine tests 2 weeks, 1 month, 3 months, 6 months, 9 months and 12 months after taking the first tablet

Conditions

  • Cardiac Remodeling

Interventions

  • BaxdrostatDrug

    Participants will take 2mg baxdrostat (Baxfendy) once daily (orally), in addition to standard-of-care.

  • PlaceboDrug

    Participants will take placebo once daily (orally), in addition to standard-of-care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Left Ventricular Mass indexed to baseline body surface area (LVMi)Time frame: 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • North York Diagnostic and Cardiac Centre

    North York, Ontario, Canada

  • Diagnostic Assessment Centre

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.